相关临床试验
7
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2005
进行中（未招募）
1
14.3%
已完成
3
42.9%
尚未招募
2
28.6%
撤回
1
14.3%
暂无批准数据
- Scancell's iSCIB1+ DNA immunotherapy delivered via PharmaJet's needle-free injection system achieved 74% progression-free survival at 16 months in advanced melanoma patients. - The Phase 2 SCOPE trial results significantly outperformed standard checkpoint inhibitor therapy, which showed 50% progression-free survival at 11.5 months. - Based on these promising results, Scancell plans to initiate a registrational Phase 3 study in the second half of 2026. - The company aims to advance iSCIB1+ toward potential commercialization by 2029, addressing a critical unmet need in advanced melanoma treatment.
- PharmaJet is developing a suite of proprietary needle-free self-injection pens for subcutaneous delivery of chronic disease treatments and metabolic peptides, currently in early testing phases. - The company's existing Tropis intradermal system has demonstrated superior user acceptance with over 95% caregiver preference and significant reductions in patient-reported pain and soreness compared to traditional needle injections. - Clinical evidence shows needle-free delivery can improve patient compliance rates, with PharmaJet's technology having been used for over 12 million vaccine injections worldwide. - The new pen injectors will incorporate smart e-technology for dose tracking and aim to address needle aversion barriers that impact treatment compliance in chronic disease management.
- Immuno Cure and PharmaJet signed a collaboration agreement to evaluate the HIV therapeutic DNA vaccine ICVAX using PharmaJet's needle-free Tropis intradermal delivery system in clinical trials. - The partnership builds on ICVAX's successful Phase I trial results showing exceptional safety and promising immunogenicity profiles for achieving HIV virological control without antiretroviral therapy. - The study will be conducted at Prince of Wales Hospital in Hong Kong and leverages intradermal delivery to potentially enhance immune responses through the rich network of immune cells in the dermal layer. - This collaboration represents a significant step toward developing a functional cure for HIV/AIDS, addressing the critical need for effective immunotherapy beyond current antiretroviral treatments.
- The needle-free injection system market is projected to grow at a CAGR of 4% from $606 million in 2024 to 2035, driven by increasing chronic disease prevalence and patient preference for painless administration. - Microneedle devices market is expected to reach $2.11 billion in 2024 and grow at a faster CAGR of 6.2%, reflecting technological innovations and applications in personalized medicine. - Key market players include Antares Pharma (acquired by Halozyme), INOVIO Pharmaceuticals, PharmaJet, and 3M, with technological advancements focusing on improved safety, accuracy, and patient compliance.
• PharmaJet's Tropis needle-free delivery system has demonstrated significant benefits in routine immunization programs across multiple African countries, including Nigeria, Somalia, and Pakistan. • The company will showcase its innovative needle-free intradermal delivery technology at the upcoming Ethiopian Medical Association's 61st Annual Medical Conference in February 2025. • Clinical evidence from multiple countries supports the effectiveness of PharmaJet's technology, particularly in mass vaccination campaigns and routine immunization programs.
